FindTrial
Sign In

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults with Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection (GIFT I)

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults with Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection (GIFT I)

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222350
Enrollment
Unknown
Registered
2013-12-27
Start date
2013-12-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C Virus

Interventions

investigational material(s) Generic name etc : ABT-450/Ritonavir/ABT-267 INN of investigational material : Therapeutic category code : 625 Anti-virus agents Dosage and Administration for Investigatio

Sponsors

AbbVie GK
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Chronic HCV infection prior to study enrollment - Screening laboratory result indicating HCV subgenotype 1b infection - Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening - Voluntarily sign an informed consent

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026